MC
IBB icon

Matisse Capital’s iShares Biotechnology ETF IBB Stock Holding History

Matisse Capital’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Hold
1,311
– – 0.1% 145
2026
Q1 		$221K Buy
1,311
+3
+0.2% +$513 0.09% 159
2025
Q4 		$221K Buy
+1,308
New +$212K 0.1% 161
2023
Q4 		– Sell
-6,233
Closed -$762K – 203
2023
Q3 		$762K Hold
6,233
– – 0.54% 63
2023
Q2 		$791K Hold
6,233
– – 0.49% 67
2023
Q1 		$805K Buy
+6,233
New +$816K 0.52% 67

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Matisse Capital's IBB Position: Q2 2026 in Review

Matisse Capital held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 1,311 shares worth $249K. The position accounts for 0.1% of the portfolio, ranked #145.

Matisse Capital first reported a position in IBB in Q1 2023 and has held it in 6 quarters since. The position peaked at $805K in Q1 2023. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Matisse Capital held 1,311 shares of iShares Biotechnology ETF worth $249K as of Q2 2026.
  • Matisse Capital left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up 0.1% of Matisse Capital's portfolio in Q2 2026, its #145 holding.
  • Matisse Capital first reported a position in iShares Biotechnology ETF in Q1 2023 and has held it in 6 quarters since.
  • Matisse Capital's iShares Biotechnology ETF position peaked at $805K in Q1 2023.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Matisse Capital's 13F filing for Q2 2026, filed 12 Aug 2026.